Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elena Arbelo is active.

Publication


Featured researches published by Elena Arbelo.


Journal of the American College of Cardiology | 2011

Noninvasive Identification of Ventricular Tachycardia-Related Conducting Channels Using Contrast-Enhanced Magnetic Resonance Imaging in Patients With Chronic Myocardial Infarction Comparison of Signal Intensity Scar Mapping and Endocardial Voltage Mapping

Esther Pérez-David; Angel Arenal; José L. Rubio-Guivernau; Roberto del Castillo; Leonardo Atea; Elena Arbelo; Eduardo Caballero; Verónica Celorrio; Tomás Datino; Esteban González-Torrecilla; Felipe Atienza; Maria J. Ledesma-Carbayo; Javier Bermejo; Alfonso Medina; Francisco Fernández-Avilés

OBJECTIVES We performed noninvasive identification of post-infarction sustained monomorphic ventricular tachycardia (SMVT)-related slow conduction channels (CC) by contrast-enhanced magnetic resonance imaging (ceMRI). BACKGROUND Conduction channels identified by voltage mapping are the critical isthmuses of most SMVT. We hypothesized that CC are formed by heterogeneous tissue (HT) within the scar that can be detected by ceMRI. METHODS We studied 18 consecutive VT patients (SMVT group) and 18 patients matched for age, sex, infarct location, and left ventricular ejection fraction (control group). We used ceMRI to quantify the infarct size and differentiate it into scar core and HT based on signal-intensity (SI) thresholds (>3 SD and 2 to 3 SD greater than remote normal myocardium, respectively). Consecutive left ventricle slices were analyzed to determine the presence of continuous corridors of HT (channels) in the scar. In the SMVT group, color-coded shells displaying ceMRI subendocardial SI were generated (3-dimensional SI mapping) and compared with endocardial voltage maps. RESULTS No differences were observed between the 2 groups in myocardial, necrotic, or heterogeneous mass. The HT channels were more frequently observed in the SMVT group (88%) than in the control group (33%, p < 0.001). In the SMVT group, voltage mapping identified 26 CC in 17 of 18 patients. All CC corresponded, in location and orientation, to a similar channel detected by 3-dimensional SI mapping; 15 CC were related to 15 VT critical isthmuses. CONCLUSIONS SMVT substrate can be identified by ceMRI scar heterogeneity analysis. This information could help identify patients at risk of VT and facilitate VT ablation.


Circulation-arrhythmia and Electrophysiology | 2012

Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique

Antonio Berruezo; Juan Fernández-Armenta; Lluis Mont; Hrvojka Zeljko; David Andreu; Csaba Herczku; Tim Boussy; José María Tolosana; Elena Arbelo; Josep Brugada

Background— Ventricular tachycardia (VT) ablation in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) has a low success rate. A more extensive epicardial (Epi) arrhythmogenic substrate could explain the low efficacy. We report the results of combined endocardial (Endo) and Epi VT ablation and conducting channel (CC) elimination. Methods and Results— Eleven consecutive patients with ARVD/C were included in the study. A high-density 3D Endo (321±93 sites mapped) and Epi (302±158 sites mapped) electroanatomical voltage map was obtained during sinus rhythm to define scar areas (<1.5 mV) and CCs inside the scars, between scars, or between the tricuspid annulus and a scar. The end point of the ablation procedure was the elimination of all identified CCs (scar dechanneling) and the abolition of all inducible VTs. The mean procedure and fluoroscopy time were 177±63 minutes and 20±8 minutes, respectively. Epi scar area was larger in all cases (26±18 versus 94±45 cm2, P<0.01). The combined Endo and Epi VT ablation eliminated all clinical and induced VTs, and the addition of scar dechanneling resulted in noninducibility in all cases. Seven patients continued on sotalol. During a median follow-up of 11 months (6–24 months), only 1 (9%) patient had a VT recurrence. There was a single major bleeding event that did not preclude a successful procedure. Conclusions— Combined Endo and Epi mapping reveals a wider Epi VT substrate in patients with ARVD/C with clinical VTs. As a first-line therapy, combined Endo and Epi VT ablation incorporating scar dechanneling achieves a very good short- and midterm success rate.


European Heart Journal | 2014

The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association

Elena Arbelo; Josep Brugada; Gerhard Hindricks; Aldo P. Maggioni; Luigi Tavazzi; Panos E. Vardas; Cécile Laroche; Frederic Anselme; Giuseppe Inama; Pierre Jaïs; Zbigniew Kalarus; Josef Kautzner; Thorsten Lewalter; Georges H. Mairesse; Julián Pérez-Villacastín; Sam Riahi; Milos Taborsky; George N. Theodorakis; Serge A. Trines

AIMS The Atrial Fibrillation Ablation Pilot Study is a prospective registry designed to describe the clinical epidemiology of patients undergoing an atrial fibrillation (AFib) ablation, and the diagnostic/therapeutic processes applied across Europe. The aims of the 1-year follow-up were to analyse how centres assess in routine clinical practice the success of the procedure and to evaluate the success rate and long-term safety/complications. METHODS AND RESULTS Seventy-two centres in 10 European countries were asked to enrol 20 consecutive patients undergoing a first AFib ablation procedure. A web-based case report form captured information on pre-procedural, procedural, and 1-year follow-up data. Between October 2010 and May 2011, 1410 patients were included and 1391 underwent an AFib ablation (98.7%). A total of 1300 patients (93.5%) completed a follow-up control 367 ± 42 days after the procedure. Arrhythmia documentation was done by an electrocardiogram in 76%, Holter-monitoring in 52%, transtelephonic monitoring in 8%, and/or implanted systems in 4.5%. Over 50% became asymptomatic. Twenty-one per cent were re-admitted due to post-ablation arrhythmias. Success without antiarrhythmic drugs was achieved in 40.7% of patients (43.7% in paroxysmal AF; 30.2% in persistent AF; 36.7% in long-lasting persistent AF). A second ablation was required in 18% of the cases and 43.4% were under antiarrhythmic treatment. Thirty-three patients (2.5%) suffered an adverse event, 272 (21%) experienced a left atrial tachycardia, and 4 patients died (1 haemorrhagic stroke, 1 ventricular fibrillation in a patient with ischaemic heart disease, 1 cancer, and 1 of unknown cause). CONCLUSION The AFib Ablation Pilot Study provided crucial information on the epidemiology, management, and outcomes of catheter ablation of AFib in a real-world setting. The methods used to assess the success of the procedure appeared at least suboptimal. Even in this context, the 12-month success rate appears to be somewhat lower to the one reported clinical trials.


Journal of Cardiovascular Electrophysiology | 2013

Left Atrial Sphericity: A New Method to Assess Atrial Remodeling. Impact on the Outcome of Atrial Fibrillation Ablation

Felipe Bisbal; Esther Guiu; Naiara Calvo; David Marín; Antonio Berruezo; Elena Arbelo; José T. Ortiz-Pérez; Teresa M. de Caralt; José María Tolosana; Roger Borràs; Marta Sitges; Josep Brugada; Lluis Mont

Atrial fibrillation (AF) ablation outcome is mainly determined by atrial remodeling that, nowadays, is only estimated through clinical presentation (persistent vs. paroxysmal) and left atrial (LA) dimension. The aim of the study was to stage the atrial remodeling process using the Left Atrial Sphericity (LASP) and determine whether this technique may help to predict AF ablation outcome.


Circulation-arrhythmia and Electrophysiology | 2015

Scar Dechanneling New Method for Scar-Related Left Ventricular Tachycardia Substrate Ablation

Antonio Berruezo; Juan Fernández-Armenta; David Andreu; Diego Penela; Csaba Herczku; Reinder Evertz; Laura Cipolletta; Juan Acosta; Roger Borràs; Elena Arbelo; José María Tolosana; Josep Brugada; Lluis Mont

Background—Ventricular tachycardia (VT) substrate ablation usually requires extensive ablation. Scar dechanneling technique may limit the extent of ablation needed. Methods and Results—The study included 101 consecutive patients with left ventricular scar–related VT (75 ischemic patients; left ventricular ejection fraction, 36±13%). Procedural end point was the elimination of all identified conducting channels (CCs) by ablation at the CC entrance followed by abolition of residual inducible VTs. By itself, scar dechanneling rendered noninducibility in 54.5% of patients; ablation of residual inducible VT increased noninducibility to 78.2%. Patients needing only scar dechanneling had a shorter procedure (213±64 versus 244±71 minutes; P=0.027), fewer radiofrequency applications (19±11% versus 27±18%; P=0.01), and external cardioversion/defibrillation shocks (20% versus 65.2%; P<0.001). At 2 years, patients needing scar dechanneling alone had better event-free survival (80% versus 62%) and lower mortality (5% versus 11%). Incomplete CC-electrogram elimination was the only independent predictor (hazard ratio, 2.54 [1.06–6.10]) for the primary end point. Higher end point-free survival rates were observed in patients noninducible after scar dechanneling (log-rank P=0.013) and those with complete CC-electrogram elimination (log-rank P=0.013). The complications rate was 6.9%, with no deaths. Conclusions—Scar dechanneling alone results in low recurrence and mortality rates in more than half of patients despite the limited ablation extent required. Residual inducible VT ablation improves acute results, but patients who require it have worse outcomes. Recurrences are mainly related to incomplete CC-electrogram elimination.


Journal of Cardiovascular Electrophysiology | 2010

Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia

Elena Arbelo; F.A.C.C. Mark E. Josephson M.D.

VT Ablation in Right Ventricular Dysplasia.  Arrhythmogenic right ventricular dysplasia (ARVD) is a genetically determined myocardial disease characterized by fibrofatty replacement of the right ventricular wall. Ventricular tachyarrhythmias can be seen in the early stages of the disease, which is one of the most important causes of sudden death in young healthy individuals. Radiofrequency (RF) catheter ablation is an option for the treatment of medically refractory ventricular arrhythmias and it has shown to successfully abolish recurrent ventricular tachycardias (VT) as well as reduce the frequency in defibrillator therapies. However, variable acute and long‐term success rates have been reported. The current mapping and ablation techniques include activation and entrainment mapping during tolerated VT and substrate ablation using 3‐dimensional electroanatomic mapping systems. This article aims at providing a comprehensive review of RF catheter ablation of ventricular arrhythmias in the context of ARVD. (J Cardiovasc Electrophysiol, Vol. 21, pp. 473‐14, April 2010)


Genetics in Medicine | 2016

Brugada syndrome: clinical and genetic findings.

Georgia Sarquella-Brugada; Oscar Campuzano; Elena Arbelo; Josep Brugada; Ramon Brugada

Brugada syndrome is a rare, inherited cardiac disease leading to ventricular fibrillation and sudden cardiac death in structurally normal hearts. Clinical diagnosis requires a Brugada type I electrocardiographic pattern in combination with other clinical features. The most effective approach to unmasking this diagnostic pattern is the use of ajmaline and flecainide tests, and the most effective intervention to reducing the risk of death is the implantation of a cardioverter defibrillator. To date, 18 genes have been associated with the disease, with the voltage-gated sodium channel α type V gene (SCN5A) being the most common one to date. However, only 30–35% of diagnosed cases are attributable to pathogenic variants in known genes, emphasizing the need for further genetic studies. Despite recent advances in clinical diagnoses and genetic testing, risk stratification and clinical management of patients with Brugada syndrome remain challenging.Genet Med 18 1, 3–12.


European Heart Journal | 2017

Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry

Elena Arbelo; Josep Brugada; Carina Blomström Lundqvist; Cécile Laroche; Josef Kautzner; Evgeny Pokushalov; Pekka Raatikainen; Michael Efremidis; Gerhard Hindricks; Alberto Barrera; Aldo P. Maggioni; Luigi Tavazzi; Nikolaos Dagres

Aims The ESC-EHRA Atrial Fibrillation Ablation Long-Term registry is a prospective, multinational study that aims at providing an accurate picture of contemporary real-world ablation for atrial fibrillation (AFib) and its outcome. Methods and results A total of 104 centres in 27 European countries participated and were asked to enrol 20–50 consecutive patients scheduled for first and re-do AFib ablation. Pre-procedural, procedural and 1-year follow-up data were captured on a web-based electronic case record form. Overall, 3630 patients were included, of which 3593 underwent an AFib ablation (98.9%). Median age was 59 years and 32.4% patients had lone atrial fibrillation. Pulmonary vein isolation was attempted in 98.8% of patients and achieved in 95–97%. AFib-related symptoms were present in 97%. In-hospital complications occurred in 7.8% and one patient died due to an atrioesophageal fistula. One-year follow-up was performed in 3180 (88.6%) at a median of 12.4 months (11.9–13.4) after ablation: 52.8% by clinical visit, 44.2% by telephone contact and 3.0% by contact with the general practitioner. At 12-months, the success rate with or without antiarrhythmic drugs (AADs) was 73.6%. A significant portion (46%) was still on AADs. Late complications included 14 additional deaths (4 cardiac, 4 vascular, 6 other causes) and 333 (10.7%) other complications. Conclusion AFib ablation in clinical practice is mostly performed in symptomatic, relatively young and otherwise healthy patients. Overall success rate is satisfactory, but complication rate remains considerable and a significant portion of patients remain on AADs. Monitoring after ablation shows wide variations. Antithrombotic treatment after ablation shows insufficient guideline-adherence.


European Journal of Heart Failure | 2014

EAARN score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on pre‐implantation risk factors

Malek Khatib; José María Tolosana; Emilce Trucco; Roger Borràs; A. Castel; Antonio Berruezo; Adelina Doltra; Marta Sitges; Elena Arbelo; Maria Matas; Josep Brugada; Lluis Mont

The beneficial effects of CRT in patients with advanced heart failure, wide QRS, and low LVEF have been clearly established. Nevertheless, mortality remains high in some patients. The aims of our study were to identify the predictors of mortality in patients treated with CRT and to design a risk score for mortality.


International Journal of Cardiology | 2013

Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation

Naiara Calvo; Felipe Bisbal; Esther Guiu; Pablo Ramos; Mercè Nadal; José María Tolosana; Elena Arbelo; Antonio Berruezo; Marta Sitges; Josep Brugada; Lluis Mont

INTRODUCTION Atrial fibrillation (AF) is a recognized treatable cause of tachycardiomyopathy (TMP), with class IIb indication for catheter ablation (CA). The aim of this study is to analyze the prevalence, clinical characteristics and effect of CA in patients with TMP and to evaluate TMP as a prognostic factor for AF recurrence in these patients (TMP group), compared to controls with normal left ventricular ejection fraction (LVEF) and patients with heart failure due to structural cardiomyopathy (HF group). METHODS AND RESULTS The study groups included 659 consecutive patients undergoing CA between 2003 and 2011: TMP group (n = 61), HF group (n = 36) and control group (n = 562). Compared to controls, patients with TMP were younger, had a shorter AF course and more often had persistent AF. Regarding echocardiographic parameters, the TMP group had lower LVEF (40% vs. 62%, P < 0.05), larger left atrial diameter (LAD: 46 vs. 41 mm, P < 0.05) and LV end-diastolic diameter (LVEDD: 55 vs. 51 mm, P < 0.05) compared to controls, with significant improvement at six-month follow-up, including those patients with AF recurrence. The probability of being arrhythmia-free did not differ between the TMP group and the other groups after a first or last procedure. The only independent predictor of AF recurrence was LAD. CONCLUSIONS Patients with tachycardiomyopathy secondary to AF benefit from CA, with a significant improvement in LVEF, LVEDD and LAD. The outcome after CA of this group did not differ from patients with no structural cardiomyopathy.

Collaboration


Dive into the Elena Arbelo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lluis Mont

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marta Sitges

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

David Andreu

Pompeu Fabra University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge